Buyers list leaked; Wisconsin puppy mill customer defends research
The Brief
A whistle-blower with access to an internal Ridglan Farms database has given FOX6 Investigators a list of customers who bought beagle puppies in 2019 and 2020.
FOX6 Investigators are releasing the names of the ten largest customers (by number of dogs purchased).
The founder of East Tennessee Clinical Research calls himself a "loyal" Ridglan Farms customer and defends the embattled breeder's practice of performing "cherry eye" surgeries on dogs with little or no anesthetic.
BLUE MOUNDS, Wis. - Every year, Ridglan Farms in Wisconsin sells more than 3,000 beagle puppies bred for scientific research. Now, we know who is buying them.
What we know
An anonymous source provided FOX6 Investigators with a complete list of customers who purchased beagle puppies in 2019 and 2020. The purchases are perfectly legal, but public scrutiny of what happens to the dogs at Ridglan Farms has increased since a Dane County judge appointed a special prosecutor earlier this year to investigate animal cruelty charges. Former employees testified last fall that dogs are kept in cages 24 hours a day with minimal human contact and that non-veterinarians are directed to perform painful, but routine surgical procedures on the animals without anesthesia.
According to the data provided to FOX6 (which Ridglan Farms neither confirmed nor asked us to correct), the number one buyer over that two-year period was NASCO, a biological supply company for educators based in Fort Atkinson, Wisconsin. NASCO bought 1,736 Ridglan dogs during that time, but it's not clear how they are using the animals or what happens when they are finished.
Number two was TRS Labs, a research and development laboratory in Athens, Georgia.
The third-largest customer was the Illinois Institute of Technology in Chicago. FOX6 Investigators previously reported on IIT's use of 38 Ridglan beagles for a Covid-19 drug toxicity experiment. All 38 dogs were killed on the 15th day of testing so their organs could be harvested for further testing.
FREE DOWNLOAD: Get breaking news alerts in the FOX LOCAL Mobile app for iOS or Android
FOX6 Investigators contacted the 10 largest companies on the buyers list, but 9 of them did not respond to our request for comment. Labcorp (previously known as Covance) in Madison, Wisconsin, did respond to an earlier request for comment after FOX6 Investigators found USDA records showing it uses more dogs for laboratory experiments (2,758 in 2023) than any other lab in Wisconsin. A company spokesperson wrote at the time that "Labcorp firmly believes the proper care of all research animals is fundamental to ethical scientific research and the ability to develop safe and effective new medicines that improve health and improves lives."
What they're saying
The one company that did respond was East Tennessee Clinical Research, a private laboratory on a remote farm west of Knoxville. The company's founder, Dr. Craig Reinemeyer, is a veterinarian and serves as the laboratory's scientific officer. He said he decided to speak up because public perception of animal research is tainted.
"They think we're just the wild, wild west. We're out here doing whatever we want to do. And they don't realize how heavily regulated this industry is," Reinemeyer said.
Reinemeyer said ETCR conducts experiments on dogs to test both therapeutics intended for other dogs and for drugs meant to eventually be used on humans. The Food and Drug Administration requires that all experimental drugs be proven safe and effective before human trials can begin. He said they're just following the rules and he bristles at the suggestion that what they do constitutes "abuse" or "torture," as some critics claim."The implication is that I, as a veterinarian, have completely abandoned my principles. That I am only interested in profit," Reinemeyer said. "And that I am willing to stick red-hot needles in puppies' eyeballs if somebody will pay me enough money. And that ain't the case."
SIGN UP TODAY: Get daily headlines, breaking news emails from FOX6 News
Reinemeyer said beagles make the best research animals not just because of their docile temperament, but also because of their ability to withstand life in a cage.
"Beagles tolerate confinement," Reinemeyer said.
In March, Reinemeyer wrote a two-page letter to the Wisconsin Veterinary Examining Board in defense of Dr. Richard Van Domelen, Ridglan Farms' lead veterinarian. In the letter, he wrote that he was a "loyal" customer of Ridglan. He said he visited the facility in 2024 and saw an employee playing with beagle puppies. He learned the employee's full-time job was socializing the animals. Finally, he told the board he did not think the cherry eye surgeries that are the subject of a criminal investigation constitute "animal cruelty."
The other side
The criminal investigation into Ridglan Farms was prompted by a complaint filed by an animal rights group called Dane4Dogs.
"I think it's odd that he would want to announce to the world just how low his standards are," said Rebekah Robinson, Dane4Dogs president.
Robinson said beagles may tolerate cages better than other dog breeds by comparison, but that doesn't mean it's good for them.
"Confinement is just cruelty to these animals," Robinson said. "These dogs are meant to be social animals. They are bred specifically for their attachment to humans."
Robinson also challenged the notion that animal research is "heavily regulated." Federal law requires animal research labs to set up internal committees known as Institutional Animal Care and Use Committees. They are designed to provide oversight that ensures animal testing is safe, humane and minimizes animal discomfort and pain. Robinson said those committees are commonly staffed by insiders with a vested interest in the research moving forward.
At ETCR, the principal investigator conducting the research is Craig Reinemeyer, while the chair of the IACUC is Bree Reinemeyer - his daughter.
"It's the fox guarding the henhouse," Robinson said. "They are writing their own regulations."
Reinemeyer insists the IACUC is not a rubber stamp.
"They ask us hard questions," Reinemeyer said.
Dig deeper
In 2022, Congress passed (and President Biden signed into law) the FDA Modernization Act 2.0, which allows for non-animal alternative methods to be used to prove the safety and efficacy of a drug. That means animal testing is technically not required to get an experimental drug into clinical trials. However, FDA has yet to establish rules and regulations to implement the new law.
"I actually see the FDA as being the root of the problem," said Amy Van Aartsen, founder of The Marty Project, which advocates for "novel alternative methods" like using 3-dimentional models that mimic human organs. She said traditional research labs have been resistant to the idea of change.
"And I would argue if they're not actively, you know, doing things to be part of the solution. They are part of the problem," Van Aartsen said.
Eventually, Van Aartsen said, artificial intelligence will allow for sophisticated computer models that will be far more reliable than dogs or other animals at predicting how a drug will work in humans.
But Reinemeyer said he believes non-animal testing methods are still a long way off.
"[Some say] a decade away. I think, a generation," Reinemeyer said.
What's next
Multiple investigations into possible animal mistreatment at Ridglan Farms remain ongoing.
La Crosse County DA Tim Gruenke is serving as a special prosecutor to determine if criminal charges should be filed.
The Wisconsin Veterinary Examining Board has agreed to allow Dr. Van Domelen to continue practicing while his disciplinary proceeding continues. That agreement is conditioned upon all surgeries at Ridglan being performed only by licensed vets using proper anesthesia.
Finally, the Wisconsin Department of Agriculture, Trade and Consumer Protection is also investigating possible violations of animal welfare at Ridglan that were noted by inspectors in 2024.
The Source
FOX6 Investigators relied on data from an anonymous source at Ridglan Farms, congressional legislation, FDA regulations, public records from the Veterinary Examining Board, interviews with animal rights activists, animal researchers and email communications with an attorney for Ridglan Farms.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
36 minutes ago
- Yahoo
COR Q1 Earnings Call: Specialty Expansion, RCA Impact, and International Softness Highlight Results
Healthcare distributor Cencora (NYSE:COR) met Wall Street's revenue expectations in Q1 CY2025, with sales up 10.3% year on year to $75.45 billion. Its non-GAAP profit of $4.42 per share was 7.9% above analysts' consensus estimates. Is now the time to buy COR? Find out in our full research report (it's free). Revenue: $75.45 billion vs analyst estimates of $75.7 billion (10.3% year-on-year growth, in line) Adjusted EPS: $4.42 vs analyst estimates of $4.10 (7.9% beat) Adjusted EBITDA: $1.32 billion vs analyst estimates of $1.22 billion (1.7% margin, 7.6% beat) Operating Margin: 1.4%, in line with the same quarter last year Market Capitalization: $55.09 billion Cencora's first quarter results were shaped by broad-based strength in its U.S. Healthcare Solutions segment, with management attributing growth to rising demand for specialty medications and higher utilization across health systems and specialty physician practices. CEO Bob Mauch highlighted the company's investments in end-to-end pharmaceutical services and deepening partnerships with providers as pivotal to this performance. The recent integration of Retina Consultants of America (RCA) was cited as a key contributor to gross profit margin expansion, with CFO Jim Cleary noting, 'RCA does add meaningfully to gross profit margin and operating margin… it is a higher-margin business than our core distribution business.' Management also pointed to ongoing productivity initiatives and a smaller-than-expected COVID-19 headwind as supporting factors. Looking ahead, Cencora's outlook is informed by its positioning in specialty pharmaceuticals, expectations for continued growth in the U.S. market, and ongoing integration of recent acquisitions. Management anticipates slower revenue growth in the second half of the year, citing tougher comparisons for GLP-1 products and biosimilar competition in mail-order channels. CFO Jim Cleary explained, 'We anticipate our growth will be at the bottom end of the respective ranges,' reflecting these headwinds but also suggesting potential margin benefits from product mix shifts. The company remains focused on expanding value-added services, strengthening specialty offerings across sites of care, and leveraging its data-driven insights to support both biopharma partners and healthcare providers. Management cited several operational and strategic developments as primary drivers of both quarterly results and the company's evolving competitive positioning. Specialty segment momentum: The company's specialty business, including physician practices and health systems, drove broad-based growth, supported by continued investments in services and wraparound offerings such as group purchasing organizations (GPOs) and management service organizations (MSOs). RCA integration impact: The acquisition of Retina Consultants of America contributed to margin expansion due to its higher profitability profile compared to Cencora's core distribution operations. The accounting treatment of RCA's minority interest also resulted in a higher-than-expected EPS contribution. GLP-1 product dynamics: GLP-1 (glucagon-like peptide-1) medications remained a significant revenue driver, though management noted a sequential decline from the prior quarter and minimal profit contribution. The company expects GLP-1 growth rates to moderate in upcoming quarters. International market softness: The International Healthcare Solutions segment experienced subdued demand, particularly in global specialty logistics and consulting related to clinical trials. Management described this as a market-wide issue and adjusted guidance downward to reflect slow recovery in these areas. Broad-based provider growth: Cencora reported growth across its specialty provider verticals, including oncology and retina, with management emphasizing robust positioning across community practices and health systems rather than concentration in any single sub-segment. Cencora's forward outlook is shaped by shifting specialty drug dynamics, international market uncertainty, and continued strategic investments in higher-margin services. Specialty and biosimilar expansion: Management expects specialty pharmaceuticals and biosimilars to remain key growth drivers, with continued investment in value-added services for both biopharma manufacturers and provider partners. The company's MSO and GPO offerings are designed to deepen relationships and capture a greater share of specialty market growth. International segment headwinds: The company anticipates ongoing weakness in its International Healthcare Solutions segment due to soft clinical trial activity and slower-than-expected recovery in global specialty logistics. Management revised down operating income expectations for this segment, citing industry-wide delays in clinical trial starts and subdued demand for consulting services. Product mix and margin effects: Shifts toward higher-margin specialty products and reduced contribution from lower-margin high-priced mail-order products are expected to benefit consolidated operating margins, partially offsetting slower top-line growth. Management noted that these mix effects will likely drive operating income growth above revenue growth, especially in the U.S. segment. Looking forward, the StockStory team will monitor (1) U.S. specialty drug utilization trends and the pace of biosimilar adoption, (2) the trajectory of international clinical trial activity and any signs of a rebound in specialty logistics, and (3) further integration milestones for RCA and the expansion of high-margin MSO services. The evolution of tariff policy and its potential effects on pharmaceutical supply chains will also be an important area for scrutiny. Cencora currently trades at a forward P/E ratio of 17.6×. At this valuation, is it a buy or sell post earnings? See for yourself in our full research report (it's free). Market indices reached historic highs following Donald Trump's presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth. While this has caused many investors to adopt a "fearful" wait-and-see approach, we're leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
38 minutes ago
- Yahoo
Novavax's COVID-flu combo and standalone flu shots improve immunity in late-stage study
(Reuters) -Novavax's experimental COVID-19-influenza combination and standalone influenza vaccines showed strong immune responses in some patients tested in a late-stage study, the company said on Wednesday.


Miami Herald
an hour ago
- Miami Herald
Moderna to Present at Upcoming Barclays Speaking the Science Call Series on June 16, 2025
CAMBRIDGE, MA / ACCESS Newswire / June 11, 2025 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor event: Barclays Speaking the Science Call Series, on Monday, June 16th at 10:00am ET A live webcast of this presentation will be available under "Events and Presentations" in the Investors section of the Moderna website. A replay of this webcast will be archived on Moderna's website for at least 30 days following the presentation. About Moderna Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines. Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn. Investors:Lavina TalukdarSenior Vice President & Head of Investor SOURCE: Moderna, Inc.